TransCon VEGF-TKI

N/A

Report date: 2024/06/06 11:18:58

Base Information

Drug NameTransCon VEGF-TKI

Drug Alias NameTransCon VEGF-TKI

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionVascular endothelial growth factor receptor 2 antagonistsStem cell growth factor receptor inhibitorsVascular endothelial growth factor receptor 3 antagonists +[6]

TargetsVascular endothelial growth factor receptor 2Platelet-derived growth factor receptor betaStem cell growth factor receptor +[5]

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryDenmark

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAscendis Pharma A/S

China Registration ClassN/A

Develop Information

Active CompaniesAscendis Pharma A/S

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A